Biota Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing oral, small molecule compounds to treat respiratory-related viral infections. The Company has four product candidates in development that address viral infections, which inlcude Vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; AP611074, a topical treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections, and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. In addition, the Company's Zanamivir is marketed around the world as Relenza for the prevention and treatment of Influenza A and B. Its Laninamivir Octanoate, LANI, an octanoyl ester pro-drug of laninamivir, is marketed in Japan as Inavir for the treatment and prophylaxis of influenza A and B infections.